The global potential analysis of human DNA vaccine market is segmented based on forecast scenario analysis and region. Based on forecast scenario analysis, it is divided into rapid growth scenario, moderate growth scenario, and low growth scenario. The market analysis based on region includes North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS
In-depth study of the global potential market for DNA vaccines is conducted based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030.
Potential analysis of opportunities is evaluated to understand different aspects of DNA vaccines that are currently under various phases of clinical trials along with the variants that would gain prominence in the future.
Vaccine pipeline products against DNA, which are under various clinical stages, are covered.
Key market players are profiled and their strategies are analyzed thoroughly to understand various technologies adopted to manufacture DNA vaccines.
KEY MARKET SEGMENTS
By Forecast Scenario Analysis
Rapid Growth Scenario
Moderate Growth Scenario
Low Growth Scenario
Inovio Pharmaceuticals, Inc.
GeneOne Life Science Inc.
Immunomic Therapeutics, Inc.
Astellas Pharma, Inc.
F. Hoffmann-La Roche AG
Boehringer Ingelheim GmbH
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES
CHAPTER 4 FORECAST SCENARIO ANALYSIS OF HUMAN DNA VACCINES MARKET
4.1.1. Market size & forecast
188.8.131.52. Rapid growth scenario
184.108.40.206. Moderate growth scenario
220.127.116.11. Low growth scenario
CHAPTER 5 GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY
5.2. NORTH AMERICA
5.2.1. Key opportunities
5.2.2. Market size & forecast
5.3.1. Key opportunities
5.3.2. Market size & forecast
5.4.1. Key opportunities
5.4.2. Market size & forecast
5.5.1. Key opportunities
5.5.2. Market size & forecast
CHAPTER 6 COMPANY PROFILES
6.1. INOVIO PHARMACEUTICALS, INC.
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Product pipeline
6.1.6. Research funding
6.1.7. Key strategic developments
6.2. GENEONE LIFE SCIENCE INC.
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Product pipeline
6.2.6. Research funding
6.2.7. Key strategic developments
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Product pipeline
6.3.6. Research funding
6.3.7. Key strategic developments
6.4. IMMUNOMIC THERAPEUTICS, INC.
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Product pipeline
6.4.6. Research funding
6.4.7. Strategic moves and developments
6.5. ASTELLAS PHARMA, INC.
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Product pipeline
6.5.6. Research fuding
6.5.7. Strategic moves and developments
6.6. PHAROS BIOLOGICALS
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Product pipeline
6.6.6. Research funding
6.6.7. Strategic moves and developments
6.7. SANOFI S.A.
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Product pipeline
6.7.6. Research funding
6.7.7. Strategic moves and developments
6.8. F. HOFFMANN-LA ROCHE AG
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Product pipeline
6.8.6. Research funding
6.8.7. Strategic moves and developments
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Product pipeline
6.9.6. Research fuding
6.9.7. Strategic moves and developments
6.10. BOEHRINGER INGELHEIM GMBH
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Product pipeline
6.10.6. Research funding
6.10.7. Strategic moves and developments
Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas D vaccines consist of the D sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditiol approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture. In addition, D vaccines are temperature stable, leading to easier storage and transport. D vaccition may provide an important tool for stimulating an immune response in HBV, HCV, and HIV patients, owing to their therapeutic potential for ongoing chronic viral infection. For instance, Inovios INO-3112 is in phase II clinical trial, and can be used to treat cervical cancer caused by HPV. This immunotherapy ebles the body to produce E6 and E7 antigens to induce a stronger targeted immune response against HPV-associated diseases, such as cervical cancer.
Key findings of the Potential Alysis of Human D Vaccines Market:
North America is expected to domite the market in 2020, and is projected to grow at the highest CAGR during the forecast period.
Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.
The major players profiled in the global potential alysis of human D vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.